Why the study?
Mesenchymal stem cell transplantation is a promising strategy for acute myocardial infarction, but research to date has demonstrated unsatisfactory results.
Does the combination of MSCs and anti-CCR2 improve cardiac function and reduce macrophage infiltration in an AMI mouse model?
Does the combination of MSCs and anti-CCR2 improve cardiac function and reduce macrophage infiltration in an AMI mouse model?
Combining MSC transplantation with anti-CCR2 to block monocyte recruitment synergistically improves cardiac function and reduces inflammation in a mouse model of acute myocardial infarction.
Background: Mesenchymal stem cell (MSC) transplantation is a promising therapeutic approach for acute myocardial infarction (AMI), however, research to date has demonstrated unsatisfactory results. Materials & methods: An AMI mouse model was established via left coronary artery ligation. AMI mice were treated with MSCs, anti-CCR2 or MSCs + anti-CCR2 and the effects of each treatment group were compared. Macrophage infiltration was analyzed by immunofluorescence staining and flow cytometry. Results: Implantation of MSCs + anti-CCR2 yielded a greater improvement in cardiac function and significantly reduced macrophage accumulation in the infarct site of AMI mice compared with the injection of MSCs or anti-CCR2 alone. Moreover, reduced macrophage infiltration was accompanied by reduced pro-inflammatory cytokine secretion in the injury sites and the low inflammatory response favored tissue regeneration. Conclusion: Treatment with MSCs and anti-CCR2 in combination may be a promising therapeutic strategy for AMI.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2021) studied Acute myocardial infarction (AMI). MSCs + anti-CCR2 vs. MSCs alone or anti-CCR2 alone was evaluated on Cardiac function and macrophage accumulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: